Does the media prefer AURA or IDYA?

In the previous week, IDEAYA Biosciences had 3 more articles in the media than Aura Biosciences. MarketBeat recorded 5 mentions for IDEAYA Biosciences and 2 mentions for Aura Biosciences. IDEAYA Biosciences' average media sentiment score of 0.66 beat Aura Biosciences' score of 0.43 indicating that IDEAYA Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aura Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral IDEAYA Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Is AURA or QURE more profitable?

Aura Biosciences has a net margin of 0.00% compared to uniQure's net margin of -1,350.73%. Aura Biosciences' return on equity of -73.18% beat uniQure's return on equity. Company Net Margins Return on Equity Return on Assets Aura Biosciences N/A -73.18% -62.00% uniQure -1,350.73% -111.96% -29.01%

Does the media prefer AURA or QURE?

In the previous week, Aura Biosciences and Aura Biosciences both had 2 articles in the media. uniQure's average media sentiment score of 0.48 beat Aura Biosciences' score of 0.43 indicating that uniQure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aura Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral uniQure 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is AURA or CLDX more profitable?

Celldex Therapeutics' return on equity of -52.35% beat Aura Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Aura Biosciences N/A -73.18% -62.00% Celldex Therapeutics N/A -52.35% -47.61%

Does the media prefer AURA or CLDX?

In the previous week, Celldex Therapeutics had 1 more articles in the media than Aura Biosciences. MarketBeat recorded 3 mentions for Celldex Therapeutics and 2 mentions for Aura Biosciences. Celldex Therapeutics' average media sentiment score of 0.90 beat Aura Biosciences' score of 0.43 indicating that Celldex Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aura Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Celldex Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor VCYT or AURA?

In the previous week, Veracyte had 8 more articles in the media than Aura Biosciences. MarketBeat recorded 10 mentions for Veracyte and 2 mentions for Aura Biosciences. Veracyte's average media sentiment score of 1.29 beat Aura Biosciences' score of 0.43 indicating that Veracyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veracyte 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aura Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to NAMS or AURA?

In the previous week, NewAmsterdam Pharma had 2 more articles in the media than Aura Biosciences. MarketBeat recorded 4 mentions for NewAmsterdam Pharma and 2 mentions for Aura Biosciences. NewAmsterdam Pharma's average media sentiment score of 0.89 beat Aura Biosciences' score of 0.43 indicating that NewAmsterdam Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aura Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Aura Biosciences (AURA) Competitors

$7.80 +0.03 (+0.39%)

As of 08/21/2026 04:00 PM Eastern

Compare

AURA vs. IDYA, QURE, CLDX, VCYT, and NAMS

Should you buy Aura Biosciences stock or one of its competitors? Aura Biosciences's main competitors and comparable companies include IDEAYA Biosciences (IDYA), uniQure (QURE), Celldex Therapeutics (CLDX), Veracyte (VCYT), and NewAmsterdam Pharma (NAMS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Aura Biosciences compare to IDEAYA Biosciences?

Aura Biosciences (NASDAQ:AURA) and IDEAYA Biosciences (NASDAQ:IDYA) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.

Aura Biosciences has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market. Comparatively, IDEAYA Biosciences has a beta of -0.1, suggesting that its stock price is 110% less volatile than the broader market.

In the previous week, IDEAYA Biosciences had 3 more articles in the media than Aura Biosciences. MarketBeat recorded 5 mentions for IDEAYA Biosciences and 2 mentions for Aura Biosciences. IDEAYA Biosciences' average media sentiment score of 0.66 beat Aura Biosciences' score of 0.43 indicating that IDEAYA Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aura Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
IDEAYA Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Aura Biosciences has higher earnings, but lower revenue than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.75	N/A
IDEAYA Biosciences	$218.71M	15.94	-$113.70M	-$1.94	N/A

Aura Biosciences currently has a consensus target price of $17.50, suggesting a potential upside of 124.36%. IDEAYA Biosciences has a consensus target price of $50.13, suggesting a potential upside of 26.35%. Given Aura Biosciences' higher possible upside, analysts clearly believe Aura Biosciences is more favorable than IDEAYA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81

96.8% of Aura Biosciences shares are held by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are held by institutional investors. 1.9% of Aura Biosciences shares are held by company insiders. Comparatively, 4.7% of IDEAYA Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Aura Biosciences has a net margin of 0.00% compared to IDEAYA Biosciences' net margin of -75.93%. IDEAYA Biosciences' return on equity of -16.73% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-73.18%	-62.00%
IDEAYA Biosciences	-75.93%	-16.73%	-15.34%

Summary

IDEAYA Biosciences beats Aura Biosciences on 9 of the 15 factors compared between the two stocks.

How does Aura Biosciences compare to uniQure?

Aura Biosciences (NASDAQ:AURA) and uniQure (NASDAQ:QURE) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

In the previous week, Aura Biosciences and Aura Biosciences both had 2 articles in the media. uniQure's average media sentiment score of 0.48 beat Aura Biosciences' score of 0.43 indicating that uniQure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aura Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
uniQure	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aura Biosciences has higher earnings, but lower revenue than uniQure. uniQure is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.75	N/A
uniQure	$18.67M	179.69	-$198.97M	-$4.01	N/A

96.8% of Aura Biosciences shares are held by institutional investors. Comparatively, 78.8% of uniQure shares are held by institutional investors. 1.9% of Aura Biosciences shares are held by insiders. Comparatively, 4.7% of uniQure shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Aura Biosciences has a net margin of 0.00% compared to uniQure's net margin of -1,350.73%. Aura Biosciences' return on equity of -73.18% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-73.18%	-62.00%
uniQure	-1,350.73%	-111.96%	-29.01%

Aura Biosciences has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market. Comparatively, uniQure has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market.

Aura Biosciences presently has a consensus price target of $17.50, suggesting a potential upside of 124.36%. uniQure has a consensus price target of $65.00, suggesting a potential upside of 34.38%. Given Aura Biosciences' higher probable upside, analysts clearly believe Aura Biosciences is more favorable than uniQure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
uniQure	1 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Aura Biosciences and uniQure tied by winning 7 of the 14 factors compared between the two stocks.

How does Aura Biosciences compare to Celldex Therapeutics?

Aura Biosciences (NASDAQ:AURA) and Celldex Therapeutics (NASDAQ:CLDX) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

Aura Biosciences has a beta of 0.4, meaning that its stock price is 60% less volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market.

96.8% of Aura Biosciences shares are owned by institutional investors. 1.9% of Aura Biosciences shares are owned by company insiders. Comparatively, 5.2% of Celldex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Celldex Therapeutics' return on equity of -52.35% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-73.18%	-62.00%
Celldex Therapeutics	N/A	-52.35%	-47.61%

Aura Biosciences has higher earnings, but lower revenue than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.75	N/A
Celldex Therapeutics	$1.54M	2,059.12	-$258.76M	-$4.35	N/A

Aura Biosciences currently has a consensus target price of $17.50, indicating a potential upside of 124.36%. Celldex Therapeutics has a consensus target price of $56.08, indicating a potential upside of 38.89%. Given Aura Biosciences' higher probable upside, analysts plainly believe Aura Biosciences is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

In the previous week, Celldex Therapeutics had 1 more articles in the media than Aura Biosciences. MarketBeat recorded 3 mentions for Celldex Therapeutics and 2 mentions for Aura Biosciences. Celldex Therapeutics' average media sentiment score of 0.90 beat Aura Biosciences' score of 0.43 indicating that Celldex Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aura Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Celldex Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Celldex Therapeutics beats Aura Biosciences on 10 of the 15 factors compared between the two stocks.

How does Aura Biosciences compare to Veracyte?

Veracyte (NASDAQ:VCYT) and Aura Biosciences (NASDAQ:AURA) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

Veracyte has a net margin of 20.37% compared to Aura Biosciences' net margin of 0.00%. Veracyte's return on equity of 9.26% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veracyte	20.37%	9.26%	8.61%
Aura Biosciences	N/A	-73.18%	-62.00%

Veracyte currently has a consensus price target of $54.33, suggesting a potential upside of 28.42%. Aura Biosciences has a consensus price target of $17.50, suggesting a potential upside of 124.36%. Given Aura Biosciences' higher possible upside, analysts plainly believe Aura Biosciences is more favorable than Veracyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veracyte	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
Aura Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Veracyte had 8 more articles in the media than Aura Biosciences. MarketBeat recorded 10 mentions for Veracyte and 2 mentions for Aura Biosciences. Veracyte's average media sentiment score of 1.29 beat Aura Biosciences' score of 0.43 indicating that Veracyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veracyte	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aura Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Veracyte has a beta of 1.95, suggesting that its share price is 95% more volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market.

96.8% of Aura Biosciences shares are owned by institutional investors. 1.6% of Veracyte shares are owned by company insiders. Comparatively, 1.9% of Aura Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Veracyte has higher revenue and earnings than Aura Biosciences. Aura Biosciences is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veracyte	$517.15M	6.58	$66.35M	$1.41	30.01
Aura Biosciences	N/A	N/A	-$106.19M	-$1.75	N/A

Summary

Veracyte beats Aura Biosciences on 13 of the 16 factors compared between the two stocks.

How does Aura Biosciences compare to NewAmsterdam Pharma?

NewAmsterdam Pharma (NASDAQ:NAMS) and Aura Biosciences (NASDAQ:AURA) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, media sentiment, profitability, valuation and institutional ownership.

NewAmsterdam Pharma presently has a consensus target price of $49.33, indicating a potential upside of 77.01%. Aura Biosciences has a consensus target price of $17.50, indicating a potential upside of 124.36%. Given Aura Biosciences' higher possible upside, analysts plainly believe Aura Biosciences is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93
Aura Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Aura Biosciences has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -3,644.21%. NewAmsterdam Pharma's return on equity of -34.81% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	-3,644.21%	-34.81%	-31.50%
Aura Biosciences	N/A	-73.18%	-62.00%

In the previous week, NewAmsterdam Pharma had 2 more articles in the media than Aura Biosciences. MarketBeat recorded 4 mentions for NewAmsterdam Pharma and 2 mentions for Aura Biosciences. NewAmsterdam Pharma's average media sentiment score of 0.89 beat Aura Biosciences' score of 0.43 indicating that NewAmsterdam Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewAmsterdam Pharma	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aura Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aura Biosciences has lower revenue, but higher earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$22.50M	148.07	-$203.82M	-$2.16	N/A
Aura Biosciences	N/A	N/A	-$106.19M	-$1.75	N/A

NewAmsterdam Pharma has a beta of 0.1, suggesting that its stock price is 90% less volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market.

89.9% of NewAmsterdam Pharma shares are held by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are held by institutional investors. 12.7% of NewAmsterdam Pharma shares are held by company insiders. Comparatively, 1.9% of Aura Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

NewAmsterdam Pharma beats Aura Biosciences on 9 of the 16 factors compared between the two stocks.

Get Aura Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AURA vs. The Competition

Export

Metric	Aura Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$808.90M	$4.01B	$7.36B	$12.84B
Dividend Yield	N/A	3.64%	2.54%	11.08%
P/E Ratio	-4.46	11.62	272.88	24.24
Price / Sales	N/A	1,350.19	621.86	100.14
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	2.57	16.80	13.05	6.20
Net Income	-$106.19M	-$12.50M	$3.47B	$348.59M
7 Day Performance	1.43%	3.29%	2.09%	0.08%
1 Month Performance	8.33%	8.23%	6.64%	3.88%
1 Year Performance	19.08%	55.05%	25.02%	16.98%

Aura Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AURA Aura Biosciences	1.9149 of 5 stars	$7.80 +0.4%	$17.50 +124.4%	+19.1%	$808.90M	N/A	N/A	50
IDYA IDEAYA Biosciences	2.6923 of 5 stars	$37.93 +3.8%	$50.13 +32.2%	+57.9%	$3.33B	$234.13M	N/A	80
QURE uniQure	2.9025 of 5 stars	$47.38 -1.2%	$65.00 +37.2%	+208.1%	$3.29B	$16.10M	N/A	500	Positive News
CLDX Celldex Therapeutics	2.7399 of 5 stars	$41.79 -0.3%	$55.46 +32.7%	+79.8%	$3.28B	$158K	N/A	150	Positive News
VCYT Veracyte	4.3832 of 5 stars	$40.68 -3.3%	$54.33 +33.6%	+36.5%	$3.27B	$561.90M	28.85	790	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AURA) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aura Biosciences (AURA) Competitors

AURA vs. IDYA, QURE, CLDX, VCYT, and NAMS

How does Aura Biosciences compare to IDEAYA Biosciences?

Summary

How does Aura Biosciences compare to uniQure?

Summary

How does Aura Biosciences compare to Celldex Therapeutics?

Summary

How does Aura Biosciences compare to Veracyte?

Summary

How does Aura Biosciences compare to NewAmsterdam Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AURA vs. The Competition

Aura Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aura Biosciences (AURA) Competitors

AURA vs. IDYA, QURE, CLDX, VCYT, and NAMS

How does Aura Biosciences compare to IDEAYA Biosciences?

Which has more volatility & risk, AURA or IDYA?

Does the media prefer AURA or IDYA?

Which has stronger valuation & earnings, AURA or IDYA?

Do analysts prefer AURA or IDYA?

Do insiders & institutionals hold more shares of AURA or IDYA?

Is AURA or IDYA more profitable?

Summary

How does Aura Biosciences compare to uniQure?

Does the media prefer AURA or QURE?

Which has better earnings and valuation, AURA or QURE?

Do insiders and institutionals hold more shares of AURA or QURE?

Is AURA or QURE more profitable?

Which has more risk and volatility, AURA or QURE?

Do analysts prefer AURA or QURE?

Summary

How does Aura Biosciences compare to Celldex Therapeutics?

Which has more volatility & risk, AURA or CLDX?

Do institutionals & insiders have more ownership in AURA or CLDX?

Is AURA or CLDX more profitable?

Which has better valuation & earnings, AURA or CLDX?

Do analysts recommend AURA or CLDX?

Does the media prefer AURA or CLDX?

Summary

How does Aura Biosciences compare to Veracyte?

Is VCYT or AURA more profitable?

Do analysts recommend VCYT or AURA?

Does the media favor VCYT or AURA?

Which has more volatility and risk, VCYT or AURA?

Do institutionals and insiders hold more shares of VCYT or AURA?

Which has stronger valuation and earnings, VCYT or AURA?

Summary

How does Aura Biosciences compare to NewAmsterdam Pharma?

Do analysts recommend NAMS or AURA?

Is NAMS or AURA more profitable?

Does the media refer more to NAMS or AURA?

Which has higher valuation and earnings, NAMS or AURA?

Which has more volatility & risk, NAMS or AURA?

Do institutionals & insiders have more ownership in NAMS or AURA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AURA vs. The Competition

Aura Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools